Dr. Freeman on Challenges in Treatment Selection in Melanoma

Video

In Partnership With:

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

As with many other cancer types, treatment selection is increasingly difficult as new agents and combinations rapidly emerge in the oncology landscape.

According to Freeman, looking at other tumor types is helpful in determining what therapies might be effective in melanoma. Specifically, PD-L1 as a biomarker has shown promise in lung cancer—and although it is not effective as a biomarker in melanoma—researchers found that patients who are low PD-L1 expressers are more likely to benefit from some sort of combination therapy.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute